- Blazejewski MEDI-TECH GmbH is one of the technology leaders in the field of complex 2D and 3D endoscopy and has been able to grow very strongly in recent years
- Reinhold Blazejewski, Founder and Managing Director of Blazejewski MEDI-TECH, also sells part of his shares to the Erbe Group, but remains with the company as a minority shareholder and Managing Director
- SHS joined Blazejewski MEDI-TECH as a minority shareholder at the beginning of 2020 with the aim of supporting the growth of the company and the product portfolio
- The Erbe Group develops, produces and distributes surgical products for clinics and specialist practices and is one of the co-founders of electrosurgery
The Tübingen-based investment company SHS acquired shares in the endoscope manufacturer in 2020 as part of a minority investment. The aim of the cooperation was to use SHS’s industry know-how to develop further technologies and products and to gain additional international customers and partners. This has been successively realised in recent years. In this way, the company has succeeded in expanding its customer base, bringing more managers and employees on board, further developing the 2D and 3D chip-on-the-tip technologies and expanding the production site. While Blazejewski MEDI-TECH was already one of the leading OEM manufacturers of endoscopes for medical technology prior to SHS’s investment, the company has managed to grow further during SHS’s holding period and to expand its place as one of the technology leaders for complex rod lens and 2D and 3D chip-on-the-tip endoscopy systems. Thanks to its outstanding competence, experience and position in electrosurgery and its excellent market access, the Erbe Group is now the ideal partner to support Blazejewski MEDI-TECH in driving growth and bringing further generations of innovative 2D and 3D endoscopy systems to market.
“Blazejewski MEDI-TECH GmbH has become the technological leader in the field of video endoscopy over the last 30 years. The Erbe Group is a technical world leader in the field of energetic procedures. The synergy resulting from the combination of these approaches opens up innovative approaches in the diagnosis and therapy of medical conditions. The goal is to create a “see and treat” procedure that allows the best possible therapy procedures and thus the highest possible patient benefit,” says Christian O. Erbe, CEO of the Erbe Group.
“We would like to thank SHS, which supported us with its network and deep industry know-how. With SHS, we have found an investor who appreciates and respects our individual company history. Furthermore, we are pleased to have found the perfect partner for the next steps into the company’s successful future with the Erbe Group as buyer, from which both customers and employees will benefit,” explains Blazejewski CEO Reinhold Blazejewski.
“From the very beginning, Blazejewski MEDI-TECH was an impressive example of a German medium-sized company with outstanding technologies and products and a strong team. We are pleased that we were able to support the company with our sector expertise in its further development and growth. With the Erbe Group as buyer, Blazejewski MEDI-TECH has found a truly ideal strategic partner. We wish them both all the best for their future cooperation. In addition, we look forward to continuing to support promising medical technology and healthcare companies from the SME sector on their path to success in the future,” says SHS Managing Partner Manfred Ulmer-Weber.
About SHS Gesellschaft für Beteiligungsmanagement mbH
“Building European Healthcare Champions” is the guiding principle of the Tübingen-based sector investor SHS. With this in mind, the investor specialising in healthcare investments finances and develops its portfolio companies. Since its foundation in 1993, the focus of its investments has been on expansion financing, shareholder changes and succession situations. In doing so, SHS takes both minority and majority stakes. Investors in SHS funds include pension funds, funds of funds, family offices, entrepreneurs, strategic investors and the SHS management team. The equity investment of the AIFM-registered company is up to EUR 50 million. Volumes exceeding this can be realised with a network of co-investors. SHS places a strong emphasis on ethical considerations in its investment decisions and has therefore committed itself to the guidelines of the UN PRI, an investor initiative launched by the UN Environment Programme. SHS has currently launched its sixth fund.